QL1706/Bevacizumab ± Chemotherapy in Post-ICI Non-Squamous NSCLC

NCT07134413 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

77

Enrollment

OTHER

Sponsor class

Conditions

NSCLC

Interventions

DRUG: QL1706 plus bevacizumab with or without chemotherapy

Sponsor

Guangdong Association of Clinical Trials